Market-Moving News for September 16th
Market-Moving News for September 16th
NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrolizumab For Patients With Metastatic Melanoma Who Were Refractory To Or Had Relapsed On Prior PD-1 Inhibitor Therapy
NCNA：282% | NuCana 在 ESMO 大会上公布了 2 期 Nutide: 701 研究的最终数据，该研究涉及 NUC-7738 与 Pembrolizumab 联合用于先前 PD-1 抑制剂疗法难治或复发的转移性黑色素瘤患者
ZNTL: 49% | Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA lifted the partial clinical hold on studies of azenosertib and remains on track to meet all previously disclosed data guidance for the remainder of 2024.
ZNTL：49% | Zentalis Pharmicals的股价走高，此前该公司宣布，美国食品药品管理局取消了对azenosertib研究的部分临床搁置，并有望在2024年剩余时间内实现先前披露的所有数据指导。
ITOS: -16% | iTeos Therapeutics shares are trading lower. The company announced follow-up interim data from GALAXIES Lung-201,
ITOS：-16％ | iTEOS Therapeutics的股价走低。该公司公布了来自 GALAXIES Lung-201 的后续中期数据，
